{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:04:05Z","timestamp":1788293045325,"version":"build-2803163510"},"reference-count":33,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High response rates have been reported after CD19-targeted chimeric antigen receptor\u2013modified (CD19 CAR) T-cell therapy for relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL), yet the factors associated with duration of response in this setting are poorly characterized. We analyzed long-term outcomes in 47 patients with R\/R CLL and\/or Richter transformation treated on our phase 1\/2 clinical trial of CD19 CAR T-cell therapy with an updated median follow-up of 79.6\u00a0months. Median progression-free survival (PFS) was 8.9\u00a0months, and the 6-year PFS was 17.8%. Maximum standardized uptake value (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.07-1.23; P\u00a0&amp;lt; .001) and bulky disease (\u22655\u00a0cm; HR, 2.12; 95%\u00a0CI, 1.06-4.26; P\u00a0= .034) before lymphodepletion were associated with shorter PFS. Day\u00a0+28 complete response by positron emission tomography\u2013computed tomography (HR, 0.13; 95%\u00a0CI, 0.04-0.40; P\u00a0&amp;lt; .001), day\u00a0+28 measurable residual disease (MRD) negativity by multiparameter flow cytometry (HR, 0.08; 95%\u00a0CI, 0.03-0.22; P\u00a0&amp;lt; .001), day\u00a0+28 MRD negativity by next-generation sequencing (HR, 0.21; 95%\u00a0CI, 0.08-0.51; P\u00a0&amp;lt; .001), higher peak CD8+ CAR T-cell expansion (HR, 0.49; 95%\u00a0CI; 0.36-0.68; P\u00a0&amp;lt; .001), higher peak CD4+ CAR T-cell expansion (HR, 0.47; 95%\u00a0CI; 0.33-0.69; P\u00a0&amp;lt; .001), and longer CAR T-cell persistence (HR, 0.56; 95%\u00a0CI, 0.44-0.72; P\u00a0&amp;lt; .001) were associated with longer PFS. The 6-year duration of response and overall survival were 26.4% and 31.2%, respectively. CD19 CAR T-cell therapy achieved durable responses with curative potential in a subset of patients with R\/R CLL. This trial was registered at www.clinicaltrials.gov as #NCT01865617.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023011399","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T14:01:03Z","timestamp":1695996063000},"page":"6990-7005","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed\/refractory CLL"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-4770","authenticated-orcid":false,"given":"Emily C.","family":"Liang","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4276-8774","authenticated-orcid":false,"given":"Aya","family":"Albittar","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-9389","authenticated-orcid":false,"given":"Jennifer J.","family":"Huang","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-3882","authenticated-orcid":false,"given":"Alexandre V.","family":"Hirayama","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-1773","authenticated-orcid":false,"given":"Erik L.","family":"Kimble","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-5448","authenticated-orcid":false,"given":"Aude","family":"Chapuis","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-8288","authenticated-orcid":false,"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-2159","authenticated-orcid":false,"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-4947","authenticated-orcid":false,"given":"Hans-Peter","family":"Kiem","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4688-9920","authenticated-orcid":false,"given":"Stanley R.","family":"Riddell","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-4461","authenticated-orcid":false,"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[{"name":"3Faculity of Medicine and Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8477-6919","authenticated-orcid":false,"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"issue":"19","key":"2023112720410713100_bib1","first-page":"2307","article-title":"Five-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"26","key":"2023112720410713100_bib2","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023112720410713100_bib3","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2023112720410713100_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"2023112720410713100_bib5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2023112720410713100_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2023112720410713100_bib8","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE)-Protocol Development. CTEP. 2010. Accessed 18 March 2023. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"issue":"3","key":"2023112720410713100_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023112720410713100_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122627","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL","volume":"4","author":"Geyer","year":"2019","journal-title":"JCI Insight"},{"issue":"32","key":"2023112720410713100_bib10","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2023112720410713100_bib11","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2023112720410713100_bib12","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"issue":"10402","key":"2023112720410713100_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"303","key":"2023112720410713100_bib14","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"7897","key":"2023112720410713100_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"1","key":"2023112720410713100_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2119\/molmed.2012.00303","article-title":"Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease","volume":"20","author":"Mittal","year":"2014","journal-title":"Mol Med"},{"issue":"11","key":"2023112720410713100_bib17","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1038\/s41375-021-01217-1","article-title":"Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia","volume":"35","author":"Rivas","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2023112720410713100_bib18","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3324\/haematol.2017.177808","article-title":"Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin","volume":"103","author":"D\u00fcrr","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2023112720410713100_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-\u03baB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2023112720410713100_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2023112720410713100_bib21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"2023112720410713100_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"7786","key":"2023112720410713100_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"6537","key":"2023112720410713100_bib24","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"issue":"7643","key":"2023112720410713100_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"suppl 1","key":"2023112720410713100_bib26","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.1182\/blood-2022-156822","article-title":"Efficacy and safety of CAR T-cell therapy using a fully human CD19-targeted binder in adults with relapsed\/refractory B-ALL","volume":"140","author":"Gauthier","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023112720410713100_bib27","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.1182\/blood-2022-157826","article-title":"CAR T-cell therapy for relapsed or refractory large B-cell lymphoma using a fully human CD19-targeted single chain variable fragment: results of a first-in-human phase I\/II study","volume":"140","author":"Gazeau","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023112720410713100_bib28","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1182\/blood-2022-168185","article-title":"Timing of PD-L1 blockade with durvalumab may affect outcomes of CD19 CAR-T cell therapy for relapsed\/refractory large B-cell lymphoma","volume":"140","author":"Vinaud Hirayama","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023112720410713100_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023112720410713100_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2023112720410713100_bib31","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1182\/blood-2022-169783","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"140","author":"Iacoboni","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2023112720410713100_bib32","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"2023112720410713100_bib33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcyt.2022.03.013","article-title":"Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications","volume":"24","author":"Teoh","year":"2022","journal-title":"Cytotherapy"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/6990\/2111064\/blooda_adv-2023-011399-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/6990\/2111064\/blooda_adv-2023-011399-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T15:41:33Z","timestamp":1701099693000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/22\/6990\/498171\/Factors-associated-with-long-term-outcomes-of-CD19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":33,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011399","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]}}}